Aurinia Pharmaceuticals (AUPH) saw its stock soar 5.04% in intraday trading on Tuesday, following the company's impressive third-quarter results and an optimistic outlook for 2025. The biopharmaceutical company has raised both its revenue and net product sales guidance, signaling growing confidence in its business trajectory.

The strong financial report has clearly energized investors, contributing to a remarkable run for Aurinia's stock. Over the past week, the company has seen a 13% share price return, and an even more impressive 32% gain over the past month. This recent surge is part of a broader trend, with the stock up nearly 70% year-to-date and delivering a total shareholder return of over 75% in the last twelve months.

While the recent performance has been stellar, opinions are divided on Aurinia's valuation. Some analysts suggest the stock may be overvalued, with a fair value estimate of $13.00 compared to the current price of $14.89. However, a discounted cash flow model indicates the stock might still be undervalued by 57.2%. As Aurinia continues to execute on its growth strategy, investors will be closely watching to see if the company can justify its current valuation and deliver sustained growth in the coming quarters.